Ola Landgren, Chief of the Myeloma Service at Memorial Sloan Kettering, explains disorders that predispose a person to myeloma and how they are treated. The first of those disorders is monoclonal gammopathy of undetermined significance, or MGUS; the other is smoldering myeloma. People with MGUS may be monitored and then treated if they develop multiple myeloma. People with smoldering myeloma may be monitored or may be treated through a clinical trial if they have high-risk disease. These studies are available at MSK.